Two Lymphoma Experts Join James P. Wilmot Cancer Center
Tuesday, August 06, 2002
Two nationally recognized hematologists have joined the James P. Wilmot Cancer Center to lay the foundation for one of the best hematologic malignancy programs in the Northeast. These specialists treat blood and tissue cancers including non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, and multiple myeloma.
Steven Bernstein, M.D., was named associate professor of hematology/oncology. He comes from Roswell Park Cancer Institute and specializes in the treatment of patients with lymphoproliferative and plasma cell disorders.
And, Jonathan Friedberg, M.D., joins the Wilmot Cancer Center from Dana-Farber Cancer Institute. He is a talented hematologist specializing in lymphoid malignancies.
"These are outstanding clinicians and scientists who are nationally recognized as leaders within the field," said Richard I. Fisher, M.D., director, James P. Wilmot Cancer Center and director of cancer services, Strong Health. "Bringing them to Rochester helps us advance the quality of care we provide patients and builds the strongest hematology program between Boston and Chicago."
They are among the first recruits that Fisher has brought to the Wilmot Cancer Center, following Gary Lyman, M.D., who was previously director of the Albany Medical Center's Cancer Center and Research Institute. Lyman joined the staff in May.
Fisher has announced an aggressive plan to boost research and clinical programs and build national prominence for the Wilmot Cancer Center. He will recruit 15-20 oncologists internationally recognized for their skills and innovations who will help handle the growing volume of patients but also expand translational research. These hematologists will bring novel therapeutic options to patients in the Rochester region, as they are leaders in clinical care and research.
Bernstein is an expert in lymphoma and myeloma. He is a graduate of Brandeis University and New York University School of Medicine. He completed his residency at NYU/Bellevue Hospital and fellowships at Beth Israel Hospital-Boston, and the Dana-Farber Cancer Institute, Harvard Medical School, where he worked until 1991. He was at Roswell Park Cancer Institute for more than 10 years before joining Wilmot Cancer Center in July.
"I have always been impressed by the clinical and research programs at the Wilmot Cancer Center and am excited about the opportunity to join such a fine institution," Bernstein said.
His laboratory and clinical research interests are in the development of novel immunotherapeutic approaches to the treatment of patients with lymphoproliferative disorders. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American College of Physicians, American Association for Cancer Research, American Society for Blood and Marrow Transplantation, and Cancer and Leukemia Group B. He has published numerous articles and book chapters.
Friedberg coordinates clinical trials for patients with indolent B-cell malignancies and Hodgkin's lymphoma. He is a graduate of Williams College and Harvard Medical School. He completed his residency in internal medicine at Massachusetts General Hospital and fellowships at Dana-Farber Cancer Institute and Harvard Medical School. He is a member of the American Society of Clinical Oncology, American Society of Hematology, and Cancer and Leukemia Group B. While at Dana-Farber, he was a member of the Rising Stars Program for Innovative Research and led a number of local and national studies of lymphoma treatment.